Burdensome Symptoms and Psychological Well-Being in Psoriasis

A complete picture of treatment success in psoriasis extends well beyond what a clinician can observe. An analysis of the POSITIVE study evaluated burdensome symptoms—including itch, pain, joint pain, and fatigue—alongside psychological well-being measured by the WHO-5 index. Francisco Kerdel, MD, FAAD, of Florida Academic Dermatology Center, describes the finding that WHO-5 scores surpassed general population norms by year 2 as a meaningful signal: it suggests that patients treated with tildrakizumab did not merely reach an acceptable baseline but achieved a level of psychological well-being that exceeds what is typical in the broader population.

Kerdel reflects that historically, dermatologists concentrated primarily on the appearance of the skin, often underestimating the symptomatic burden—and particularly the degree of itch and pain—that accompanies psoriasis. Over the past 2 decades, awareness of psoriatic arthritis has grown, but fatigue remains underexamined in routine clinical visits despite its significant impact on quality of life. He advocates for consistent, systematic inquiry into these domains at every follow-up visit, noting that psoriasis is a dynamic condition in which patients can experience symptom relapse even after initial relief.

The progressive improvement in itch over time also carries practical value in the patient-clinician conversation. Rather than treating an initial report of symptom relief as a closed chapter, Kerdel recommends ongoing inquiry at subsequent visits to ensure sustained benefit and to detect early signs of breakthrough.

Stepping back to the full POSITIVE dataset—skin clearance, high-impact area response, symptom relief, and drug persistence—Kerdel frames the collective message as transformative for the field. The arrival of biologic agents has replaced a generation of toxic, borrowed therapies with treatments that can fully clear disease, address difficult anatomical locations, and support durable well-being without cumulative toxicity.